ExLibris header image
SFX Logo
Title: Enhancing Anti-PD-1/PD-L1 Immune Checkpoint Inhibitory Cancer Therapy by CD276-Targeted Photodynamic Ablation of Tumor Cells and Tumor Vasculature
Source:

Molecular Pharmaceutics [1543-8384] Bao, Rui yr:2018


Collapse list of basic services Basic
Full text
Full text available via American Chemical Society Journals
GO
Document delivery
Request document via Library/Bibliothek GO
Users interested in this article also expressed an interest in the following:
1. Riaz, N. "Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab." Cell 171.4 (2017): 934-4294967295. Link to SFX for this item
2. "Nivolumab instills hope in a hopeless situation in advanced nonsmall cell lung cancer with poor performance status." Indian journal of cancer. 54.1: 55-56. Link to SFX for this item
3. Carbone, L. "First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer." The New England Journal of Medicine 376.25 (2017): 2415-2426. Link to SFX for this item
4. Hirsch, Fred R. "PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the "Blueprint PD-L1 IHC Assay Comparison Project"." Journal of thoracic oncology 12.2 (2016): 208-222. Link to SFX for this item
5. Malik, Deepinder S. "Topical drug delivery systems: a patent review." Expert opinion on therapeutic patents 26.2 (2016): 213-228. Link to SFX for this item
6. Dushek, O. "Mechanisms for T cell receptor triggering." Nature reviews. Immunology 11.1 (2010): 47-55. Link to SFX for this item
7. Mazieres, J. "Nivolumab for treating non-small cell lung cancer." Expert opinion on biological therapy 15.12 (2015): 1789-1797. Link to SFX for this item
8. "Decision support systems for incurable non-small cell lung cancer: a systematic review." BMC medical informatics and decision making. 17.1: 144-. Link to SFX for this item
9. "Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of Nivolumab." Journal of blood medicine. 8: 41-54. Link to SFX for this item
10. Gunturi, A. "Nivolumab for the treatment of cancer." Expert opinion on investigational drugs 24.2 (2014): 1-8. Link to SFX for this item
11. Weiss, A. "Insights into the initiation of TCR signaling." Nature Immunology 15.9 (2014): 798-807. Link to SFX for this item
12. Koretzky, G. "T Cell Activation." Annual Review of Immunology 27.1 (2009): 591-619. Link to Full Text for this item Link to SFX for this item
13. Keating, Gillian M. "Nivolumab: A Review in Advanced Squamous Non-Small Cell Lung Cancer." Drugs 75.16 (2015): 1925-1934. Link to SFX for this item
14. Dushek, O. "Non-catalytic tyrosine-phosphorylated receptors." Immunological reviews 250.1 (2012): 258-276. Link to Full Text for this item Link to SFX for this item
15. Joseph, Richard W. "Nivolumab treatment for advanced renal cell carcinoma: Considerations for clinical practice." Urologic oncology 35.4 (2017): 142-148. Link to SFX for this item
16. Dushek, O. "Non‐catalytic tyrosine‐phosphorylated receptors." Immunological reviews 250.1 (2012): 258-276. Link to Full Text for this item Link to SFX for this item
17. Dushek, O. "Elementary steps in T cell receptor triggering." Frontiers in immunology 2 (2011): 91-91. Link to Full Text for this item Link to SFX for this item
18. Eramo, A. "Lung cancer stem cells: tools and targets to fight lung cancer." Oncogene 29.33 (2010): 4625-4635. Link to Full Text for this item Link to SFX for this item
19. Johrens, K. "Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas." Modern Pathology 29.10 (2016): 1165-1172. Link to Full Text for this item Link to SFX for this item
20. Barsoum, Ivraym B. "A Mechanism of Hypoxia-Mediated Escape from Adaptive Immunity in Cancer Cells." Cancer research 74.3 (2014): 665-674. Link to SFX for this item
View More...
View Less...
Select All Clear All

Expand list of advanced services Advanced
A service provided by the Library of the Wissenschaftspark Albert Einstein, Potsdam, Germany.
© 2005 SFX by Ex Libris Inc.